The economic face of epigenetic signature in cancer prevention

WCRJ 2015; 2 (2): e512

Defining the better algorithm for the accurate identification of HPV status among oropharyngeal squamous-cell carcinoma. Results from a pilot study

WCRJ 2015; 2 (1): e497

Selected Pharmacogenetic panel test for toxicity prevention of drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy

WCRJ 2015; 2 (1): e492

Liver resection for HCC in HIV-infected patients: a single center experience

WCRJ 2015; 2 (1): e490

Hepatocellular carcinoma: an overview of clinico-pathological and molecular perspectives

WCRJ 2015; 2 (1): e485

Pharmacogenomics of Cytochrome P450 Family enzymes: implications for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (1): e483

Malignant hepatic tumors in pediatric patients: clinical and radiological features

WCRJ 2015; 2 (1): e481

Study of epigenetic alteration of the promoter region of p16, BRCA1, GSTP1 genes and sporadic breast cancer

WCRJ 2015; 2 (1): e479

Pre-operative chemotherapy for colorectal cancer with liver metastases and conversion therapy

WCRJ 2015; 2 (1): e473

Vinflunine in metastatic bladder cancer

WCRJ 2015; 2 (1): e471

• Newer
• 1
• …
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• Older